Bangor Savings Bank Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bangor Savings Bank trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 952 shares of the biopharmaceutical company’s stock after selling 64 shares during the quarter. Bangor Savings Bank’s holdings in Regeneron Pharmaceuticals were worth $678,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. Sachetta LLC boosted its stake in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the last quarter. Adirondack Trust Co. lifted its holdings in Regeneron Pharmaceuticals by 2.4% in the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after acquiring an additional 10 shares during the period. UMB Bank n.a. boosted its position in Regeneron Pharmaceuticals by 1.1% in the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after purchasing an additional 10 shares in the last quarter. Trust Co. of Vermont boosted its position in Regeneron Pharmaceuticals by 8.3% in the 3rd quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 12 shares in the last quarter. Finally, Brighton Jones LLC grew its stake in shares of Regeneron Pharmaceuticals by 1.5% during the 2nd quarter. Brighton Jones LLC now owns 920 shares of the biopharmaceutical company’s stock worth $967,000 after purchasing an additional 14 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 0.3 %

REGN stock opened at $716.26 on Tuesday. The company has a market cap of $78.71 billion, a price-to-earnings ratio of 17.72, a PEG ratio of 2.19 and a beta of 0.10. The firm has a 50-day moving average of $764.19 and a two-hundred day moving average of $970.66. Regeneron Pharmaceuticals, Inc. has a 12 month low of $693.00 and a 12 month high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on REGN. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Royal Bank of Canada lowered their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, JPMorgan Chase & Co. dropped their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,052.90.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.